.
MergerLinks Header Logo

Announced

General Catalyst and T. Rowe Price led a $167m Series D financing round of Color Genomics.

Financials

Edit Data
Transaction Value£122m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Venture Capital

Software

health technology

Private

Friendly

Private Equity

Cross Border

Acquisition

United States

Completed

Minority

Synopsis

Edit

General Catalyst, an American venture capital firm, and T. Rowe Price, an American publicly owned global investment management firm, led a $167m Series D financing round of Color Genomics, a provider of health care software solutions. Viking Global also participated in a round. "We are building the rails for a national technology-based public health infrastructure. The inability to deliver basic healthcare services during the biggest health crisis of our lifetime is a direct consequence of the lack of a public health delivery model. Public health does not only mean a government-funded model. A modern public health infrastructure should enable all of the stakeholders in the health of large populations – including governments, employers, and schools – to support the essential health needs of the people they serve. By investing in the technology that ensures easy and affordable access to healthcare, we're creating the infrastructure that will serve us for decades to come," Othman Laraki, Color CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US